Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Rare disease research: grey literature is the new knowledge currency

Posted on March 27th, 2020 by

Pharma research for rare disease is challenging because of insufficient patient populations available for clinical trials, and also because the investment returns are marginal. Thus, grey literature is an important source of information for rare disease research—and, fortunately, grey literature data is increasingly being recognized as highly valuable to the scientific community.


When insights from pharma help fight fungus

Posted on March 24th, 2020 by

Fungicide resistance is a growing problem, as evidenced by publication trends. Publications on this issue are particularly high across the world’s major economies, and many focus specifically on the fungus Botrytis.


Personal Health Train initiative gives researchers data access FAIRly

Posted on March 19th, 2020 by

Health data is everywhere. It is managed by universities, research centers, medical institutions and by individuals themselves. With this valuable data located in so many disparate places, and organized differently in each place, it can be difficult for researchers to access and make use of it.


Approaches for creating a COVID-19 vaccine

Posted on March 16th, 2020 by

Before the coronavirus disease 2019 (COVID-19) pandemic, no one had ever heard of the causative agent 2019 novel coronavirus (SARS-Cov-2). There were no approved antivirals or vaccines for this virus or for any related coronaviruses (e.g., severe acute respiratory syndrome–associated coronavirus (SARS-CoV) or Middle East respiratory syndrome coronavirus).


  1. 1
  2. 2
  3. 3
  4. …
  5. 79